Raija H. Ristamaki

Turku, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Disease-phase-specific resource utilization and healthcare costs in metastatic colorectal cancer: a subgroup analysis of the Finnish RAXO study.

Disease-phase-specific resource utilization and healthcare costs in metastatic colorectal cancer: a subgroup analysis of the Finnish RAXO study.

Journal: Scandinavian journal of gastroenterology

Published: November 30, 2025

Cost-effectiveness analysis of operative versus non-operative management of colorectal cancer metastases in the Finnish RAXO Study.

Cost-effectiveness analysis of operative versus non-operative management of colorectal cancer metastases in the Finnish RAXO Study.

Journal: Acta oncologica (Stockholm, Sweden)

Published: November 08, 2025

KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts.

KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts.

Journal: BJC reports

Published: July 11, 2025

Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study).

Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study).

Journal: Cancers

Published: February 07, 2024

Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study).

Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study).

Journal: Acta oncologica (Stockholm, Sweden)

Published: November 21, 2023

Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts.

Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts.

Journal: International journal of cancer

Published: March 01, 2023

Resectability, Resections, Survival Outcomes, and Quality of Life in Older Adult Patients with Metastatic Colorectal Cancer (the RAXO-Study).

Resectability, Resections, Survival Outcomes, and Quality of Life in Older Adult Patients with Metastatic Colorectal Cancer (the RAXO-Study).

Journal: Journal of clinical medicine

Published: February 06, 2023

Resectability and resection rates of colorectal liver metastases according to RAS and BRAF mutational status: prospective study.

Resectability and resection rates of colorectal liver metastases according to RAS and BRAF mutational status: prospective study.

Journal: The British journal of surgery

Published: August 16, 2022

Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study.

Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study.

Journal: British journal of cancer

Published: February 14, 2022

Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study.

Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study.

Journal: Cancers

Published: December 31, 2021

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer.

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer.

Journal: Frontiers in oncology

Published: November 30, 2021

Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.

Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.

Journal: ESMO open

Published: October 13, 2021

Showing 1-12 of 35

Last Updated: 09/26/2026